TABLE 4.
New immunological events during years 2 and 3 of follow-up
| ID | Time (M) | Pathology | DSA specificity (max MFI) | Treatment and 3-y outcome |
|---|---|---|---|---|
| Q1m | ||||
| 045 | 13 | 1B ACR/AMR | A (7359),B (9266),DR (15,712),DQ (14,694) | Thymoglobulin, plasmapheresis/IVIG.Progressed to graft failure. |
| Q2m | ||||
| 036 | 24 | 1B ACR/AMR | DP (9890),DQ (6360) | Thymoglobulin, plasmapheresis, IVIG.Converted to q1m.Progressed to graft failure. |
| 049 | 34 | 1B ACR/AMR | DQ (44,387) | Thymoglobulin, IV steroids, plasmapheresis, IVIG.Converted to q1m. |
| 111 | 25 | Borderline | A (6847) | Oral steroid pulse.Remained on q2m.Last MFI 3759 |
ACR, acute cellular rejection; AMR, antibody-mediated rejection; DSA, donor-specific antibody; IV, intravenous; MFI, median fluorescence intensity; Q1m, every mo dosing; Q2m, every 2-mo dosing of belatacept.